[ad_1] RT @ophthopedia: Ophthopedia Update: Suprachoroidal triamcinolone acetonide improves vision in patients with macular edema https://t.co/Zwl [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] Very nice commentary, highly relevant to anyone interested in clinical trials: Are P Values Enough? https://t.co/jCOeSrkZJy [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @RetinalPhys: “If you’re interested in exploring possibilities in industry, there are a number of different ways to dip your toe in the…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @ThomasCiullaMD: Just published….Suprachoroidal Delivery of Viral and Nonviral Gene Therapy for Retinal Diseases… https://t.co/f25J [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @RetinaToday: Read our throwback article from our July/August issue where Thomas A. Ciulla, MD, MBA, discusses the clinical trials worki… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @RetinalPhys: Targeting RNA for Retinal Disease: RNA-based gene therapy is primed for a resurgence in retina. By Michael Gemayel, MD and…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @ThomasCiullaMD: Just co-authored: Retinal Physician – Targeting RNA for Retinal Disease https://t.co/u5tkg8AVOA [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] Suprachoroidal triamcinolone acetonide improves vision in patients with macular edema #ophthalmology #retina https://t.co/LMkbpeLR5T [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @ThomasCiullaMD: Our research was featured this week in Modern Retina. “How DME patients may fare differently in ‘real world’ versus tr…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @RetinalPhys: Industry Opportunities for Retina Specialists: Personal perspectives from Drs. Ciulla, Rivers, and Chang on transitioning… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.